Revlimid
For healthcare professionals only.
Looking for an optimal oral first-line treatment
for your newly diagnosed non-SCT multiple myeloma patients?

View data now

For healthcare professionals only.

X
Beam Revlimid

In non-transplant
newly diagnosed MM

Continuous REVLIMID + dexamethasone

more than doubles 4-year PFS,

compared with MPT, offering proven

first-line outcomes1,2*

MM=multiple myeloma; MPT=melphalan, prednisone,
and thalidomide; PFS=progression-free survival;
SCT=stem-cell transplant.

A Foundation of Therapy in MM3

1/20  PM-WWM-REV-0019

EU Summary of Product Characteristics
Study Design and References
X

*Continuous REVLIMID + dexamethasone compared with fixed-duration REVLIMID + dexamethasone (18 cycles) and MPT.

References:
1. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. N Engl J Med. 2014;371:906-917. 2. Facon T, Dimopoulos MA, Dispenzieri A, et al. Blood. 2018;131:301-310. 3. REVLIMID [Summary of Product Characteristics]. Utrecht, Netherlands, Celgene Europe B.V.; 2018.